Nektar Therapeutics (NKTR) closed its public offering of almost 7.64 million shares, raising $460 million.
The offering included 1.03 million shares sold to underwriters exercising their option to purchase additional stock, as well as 293,103 prefunded warrants, the company said Friday in a statement.
The stock was sold at $58 a share.